Maranta, Debra

Experience

• 

  Bristol Meyers Squibb Medical

  Jan 2000 - Jun 2005

  Medical Science Liaison - Cardiovascular
• 

  Vitrectomy Chairs

  Jul 2009 - Jul 2010

  Sales And Marketing Specialist

  Small business developed by a Sydney-based Physiotherapist providing rental vitrectomy chairs for post-operative patients. I developed marketing collateral to explain patient need, risk of poor outcomes without chairs and how the chairs provided improved outcomes for patients. Development of key selling messages and identification of ophthalmologists specialising in vitrectomy operationsManaged the Brisbane and Sydney territories with a five-fold increase in the rentals of chairs over this time and expansion in customer base. Show less

• 

  Janssen pharmaceuticals

  Aug 2010 - Aug 2016

  Medical Science Liaison - Gastroenterology

  Medical lead for Raising Expectations in Gastroenterology national medical education meeting for gastroenterologists, working with the steering committee and presenter briefings in 2014, 2015, 2016 with over 150 gastroenterology HCP’s attending each meeting. Lead the Regional REIG meetings in 2013, running 5 regional REIG meetings in rural locations across Australia.Janssen medical lead for the delivery of a Cornerstones “Best of DDW” conference updates with the American Cornerstones group and a local events agency in 2015 and 2016. Managed and developed treatment algorithm for all compassionate supply requests in gastroenterology ensuring that the dosage was medically appropriate and that all compliance requirements were met for the request to be considered Recognised as an therapeutic area expert in Inflammatory Bowel Disease within Janssen. Identified unmet needs and then supported data generation activities for clinicians which resulted in publications on Infliximab Occupational Health and Safety guidelines; Acute Severe Ulcerative Colitis Consensus Guidelines; and Therapeutic Dose Monitoring for biologic consensus guidelines. Partnered with clinicians on therapeutic drug monitoring consensus guidelines to assist in providing decision points for clinicians to follow up and Acute severe ulcerative colitis guidelinesProvided insights to support cross functional team strategy developmentConducted data presentations to Health Care Professionals • Pitched idea and developed a web-based data base for patients to source infusion access within hospitals nationally to allow the ability for the patients to undertake their treatment closer to home or when travelling on holiday. Worked with an agency to develop Infusion website Show less

• 

  Merck

  Sept 2010 - Aug 2011

  Senior Product Specialist - QLD

  Rapidly assessed HCP potential and focused on high potential customer accounts. Established strong relationships with gastroenterologists and their teams via account management focus, utilising strong scientific knowledge to support needs, resulting in increased sales. Achieved significant increases in sales and strong growth for Remicade

• 

  The Janssen Pharmaceutical Companies of Johnson & Johnson

  Aug 2011 - Oct 2011

  Specialist Sales Representative - Gastroenterology

  Developed role to provide a strong focus on KOL development and planning within the Gastroenterology Immunology teamRecognised for high level of scientific knowledge and strong relationships with KOL’s, plus a strong planning and organisational focus.

• 

  The Janssen Pharmaceutical Companies of Johnson & Johnson

  Feb 2016 - Aug 2023

  Working as a Senior Medical Advisor ensuring innovative medical strategy creating synergy to brand strategy. Strong cross functional engagement, providing guidance and insights on the disease landscape and scientific product knowledge to support the commercial and extended teams. • Co-leadership of 5-year strategic plan and annual business brand plan with the commercial brand lead, supporting dermatology launch of guselkumab in psoriatic arthritis and ustekinumab for paediatric psoriasis.• Dermatology portfolio medical lead and MSL management and coaching.• Strong financial management of medical affairs and research budget consistently remaining within the 5% discrepancy threshold.• Key Opinion Leader and Stakeholder Engagement resulting in Australian College of Dermatology grant support to develop Psoriasis Consensus Guidelines; 4-year annual grant supporting First Nations Advanced Trainees education. Australian Dermatology Nurses Association: collaboration supporting nurse education by providing 9 module Biologic Up-skilling Courses for Nurses; 3-year support for Post-Graduate Nursing Dermatology Course.• Medical Education: Delivery of product education through omnichannel execution through Clinical Trial Compendium folders incorporating trial summaries and slide decks for 16 trials (2022) to enhance knowledge and access to clinical trial data. Internal lead for, “Raising Expectations in Immunology Medical Education” run as a hybrid meeting across 3 therapeutic areas with 5 individual agendas in 5 AU states. Achieving 524 attendees registered and a NPS of +75.• Data Generation: Analysis of Real World Evidence resulting in 4 abstracts which were presented at international (ICD 2021, EADV 2022) and national conferences (ACD 2022, submitted 2023). Plus author on 2 manuscripts currently submitted awaiting publication in 2023. Show less Acquired additional responsibilities in 2020 with Senior Medical Advisor role, expanded to cover the Rheumatology Portfolio Medical leadership, in addition to Dermatology medical leadership plus management of three MSL’s. This required effective prioritisation of meetings & projects to deliver leadership across two cross functional teams, develop relationships with Rheumatology KOL's to gain insights for new product launch and complete Leading People at JnJ Management Course. COVID lockdowns in March 2020, required agility and innovation converting planned HCP educational events and interactions to virtual options to enable digital utilisation of recorded materials and transition to webinars e.g. Cancellation of Dermatology and Rheumatology College in person national meetings, meant adaption of planned events to recordings for omnichannel utilisation. Janssen supported the Australian Dermatology Nurse Association delivering 9 virtual psoriasis educational modules resulting in 1235 registrations and 845 attendees over a 8 week series. Led the prelaunch medical strategy for TREMFYA in Psoriatic Arthritis and STELARA in Paediatric Psoriasis, across the Rheumatology and Dermatology involving running 4 advisory board meetings including Dermatologists (Adult and Paediatric), Rheumatologists (KOL’s and general clinicians) to support strategic and tactical plans. Led Medical Strategy and MSL data dissemination messaging and approved proactive presentations ensuring medical and brand alignment across Dermatology/Rheumatology portfolio; Collaborated with internal compliance and code team to ensure all externally facing materials were compliant with Medicine Australia requirements; Delivered strong medical support contributing to cross functional team success achieved EXCEEDS rating over 2 years. Show less Co-led Dermatology Cross Functional team formulating medical strategy for pre-launch of TREMFYA for psoriasis indication, while continuing to provide medical leadership for STELARA for psoriasis indication. Prior to PBS reimbursement, medical team focused on driving TREMFYA prelaunch plans by establishing the importance of the new mode of action and educating HCP’s on data releases from conferences. After PBS reimbursement in February 2019, the Australian launch of TREMFYA was world leading in it’s first year becoming market leader in psoriasis by May 2020. Worked closely with Global Clinical Organisation to identify clinical trial sites for future study inclusion and support clinical research team with recruitment and trial closeout. Gained global approval and established patient access program allowing ongoing treatment after trials completion, but prior to PBS reimbursement.In 2018, identified key unmet need from Dermatologists for access to biologics for paediatric psoriasis in Australia. Previously not considered due to small market size, but brand team presentation on unmet patient need to leadership team resulted in TGA and PBS submission and approval for STELARA (TGA approval Nov 2020 and PBS reimbursement October 2021).Led ‘2019 Raising Expectations in Immunology’ program, developing a two-day national conference held in Melbourne, attended by over 200 dermatology, rheumatology and gastroenterology HCPs, and patient organisations, achieving a NPS 65. My role involved steering committee meeting management supporting agenda development which covered registrar training across 3 therapeutic areas, patient advocacy group and CAPPRE workshops; opening dinner session , full day agenda focusing on autoimmune diseases; leadership of Janssen medical education and medical team in execution of speaker briefing, logistical execution; Internal communication across immunology portfolio; ; and chairing post-evaluation meeting with feed back to steering committee. Show less As a development opportunity, I acted as medical lead for STELARA pre-launch strategy in Crohn’s disease, encompassing customer mapping, medical education plans, review of global publication plans to identify data gaps in Australia, training of sales team and supporting market access team in clinician input for TGA and PBS approval. To support the STELARA launch, I collaboration with GESA (Key Stakeholder) to create a new Satellite Symposium meeting prior to the Australian Gastroenterology Week conference, and agreement for a Meet the Expert session at the conferenceInitial concept development and pre-discussions resulting in submission of Investigator Initiated Study “Aurora” for Australian efficacy and biomarker outcomes of STELARA in Crohn’s DiseasePresented clinical data at Australian and New Zealand advisory boardsManaged the development and execution of educational opportunities to support the Stelara launch (2017) for Crohn’s Disease and expand knowledge for REMICADE usage in adult and paediatric patients. this involved: Organising and coordinating 3 leading international speaker tours in Australia; Establishing innovative round table meetings and workshops at Australian Gastroenterology Week ConferenceNominated 2016 Asia Pacific Janssen MSL of the Year (KOL engagement) Winner Janssen Australia Medallion Club Award 2016 for Customer Excellence (Other)Led the development of grants valued at $300,000 over 6-year period supporting a series of masterclasses and educational programs for health care professionals Show less

  • Senior Medical Advisor - Dermatology

    Feb 2020 - Aug 2023

  • Senior Medical Advisor - Dermatology and Rheumatology

    Feb 2020 - Oct 2020

  • Medical Advisor

    Aug 2017 - Feb 2020

  • Senior Medical Science Liaison - Gastroenterology

    Feb 2016 - Aug 2017
• 

  Novartis, Australia & New Zealand

  Jun 2023 - now

  Senior Medical Science Liaison - Cardiovascular

  Senior Medical Science Liaison working in the Cardiovascular Franchise